GLP-1 in South Africa: availability, costs and how treatment works

What is GLP-1 and how does it work?

GLP-1, glucagon-like peptide-1, is a hormone your gut releases after eating. It tells the brain you are full, slows the stomach's emptying and helps the pancreas manage blood sugar. GLP-1 medicines are engineered versions of that hormone that last days instead of minutes, which is why most are injected once a week.

The practical effect is reduced hunger and earlier fullness, which makes a lower food intake sustainable rather than a willpower exercise. The class includes liraglutide and semaglutide, plus tirzepatide, which pairs GLP-1 action with a second gut hormone, GIP.

Demand in South Africa has grown accordingly. Spotlight reported that semaglutide jumped from position 170 to position 12 on medical scheme medicine-spending lists between 2023 and 2024, and by late 2025 tirzepatide had become one of the largest pharmaceutical products in the country by sales.

The molecule most people have heard of is semaglutide, explained in detail in what semaglutide is and how it works.

How did GLP-1 medicines arrive in South Africa?

The current landscape assembled quickly. Liraglutide arrived first, but the market changed shape from late 2024 as the weekly medicines landed and indications widened.

The pace matters for anyone planning treatment: the market you assess this year will not be the market of 2027, when semaglutide's main patent lapses and more competitors are expected. Per-medicine availability detail sits in Saxenda in South Africa and is Mounjaro available in South Africa.

Which GLP-1 medicines are registered in South Africa in 2026?

Three injectables in the class carry a SAHPRA weight management registration, and one household name does not.

The South African clinical practice guideline for obesity also lists two non-injectable options approved for long-term weight management, orlistat and naltrexone/bupropion tablets, alongside liraglutide and semaglutide. Oral semaglutide exists too, registered here for type 2 diabetes; where the tablet fits is covered in is there a Wegovy pill.

Movement continues: the first generic semaglutide arrived in July 2026, unpacked in the next section. Whatever the shelf looks like in any given month, the right option is decided by a doctor on assessment.

What does generic semaglutide mean for South Africa?

South Africa approved its first generic semaglutide in July 2026. SAHPRA registered Sun Pharma's version for adults with type 2 diabetes, supplied as a pre-filled multi-dose pen in two strengths, and Business Standard reported the company planning to launch within days of approval, making South Africa its second market worldwide after India.

Read the registration carefully, though. It covers type 2 diabetes, not weight management, so any weight-related use would be off-label and strictly a doctor's clinical call. It also does not touch tirzepatide, which has no registered generic anywhere.

The significance is direction. Generic entry usually starts a price slide, semaglutide's main South African patent lapses in 2027, and research cited by Doctors Without Borders suggests generic semaglutide could eventually be produced for a small fraction of current prices. Cheaper registered semaglutide would pressure published prices across the whole class.

One caution: a registered generic still reaches you only through a licensed pharmacy on a doctor-confirmed treatment plan. Sellers pushing generic semaglutide outside that route are selling something else, whatever the label says. How the registered semaglutide brands compare on the shelf today is in Ozempic in South Africa.

How much weight do people lose on GLP-1 medication?

The South African guideline summarises one-year trial data as weight loss beyond what placebo achieved: 12.5% more for semaglutide 2.4 mg and 5.4% more for liraglutide 3.0 mg. On semaglutide, 86% of trial participants lost at least 5% of body weight, against 32% on placebo. Individual results vary.

Tirzepatide's weight management registration arrived after that guideline's data cut, and its trial figures are reported separately. Numbers alone do not pick a medicine in any case: dosing schedule, side-effect profile, availability and your health history all count, and the right option is decided by a doctor on assessment.

Two findings from the same guideline keep expectations realistic. Healthy eating and activity changes alone typically deliver 3 to 5% weight loss and are still the foundation the medicine builds on. And trials consistently show weight regain when treatment stops, which is why doctors frame this as long-term treatment for a chronic condition, not a short course.

Do GLP-1 medicines help beyond weight loss?

The research case for this class has widened well beyond the scale. The clearest evidence is the SELECT trial, published in the New England Journal of Medicine: 17,604 adults with established heart disease and a BMI of 27 or more, but no diabetes, followed for more than three years. Weekly semaglutide 2.4 mg reduced major cardiovascular events, meaning heart attack, stroke or cardiovascular death, by 20% compared with placebo: events occurred in 6.5% of the semaglutide group against 8.0% on placebo. Average weight change was 9.4% against 0.9%. Individual results vary.

Follow-up analyses of the same trial point to kidney benefits, and tirzepatide carries trial evidence in obstructive sleep apnoea, one reason its dual mechanism draws research attention. That mechanism is unpacked in how tirzepatide's dual action works.

Two cautions belong next to the findings. They apply to the specific populations studied, not to everyone. And none of them changes the SAHPRA-registered indications in South Africa: a doctor weighs whether any of this evidence applies to your health picture, and the right option is decided by a doctor on assessment.

How does GLP-1 prescribing work in South Africa?

Four steps, in a fixed order. First, a doctor assesses you: weight history, health conditions, medicines, and screening for reasons this class would be unsafe. South African guidance supports treatment for a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure or sleep apnoea.

Second, where clinically appropriate, the doctor confirms a treatment plan. Third, a licensed pharmacy dispenses the medicine; the prescribing doctor's practice does not. Fourth, follow-up reviews manage the dose step-ups and any side effects over the following months.

The assessment can lawfully happen online. Telehealth consultations with HPCSA-registered doctors are an established part of South African practice, and the pharmacy step works the same way afterwards. The sequence is the same whichever doctor and pharmacy are involved.

Where is it legal to buy GLP-1 in South Africa?

From a licensed pharmacy, after a doctor's assessment and authorisation, and nowhere else. Dischem, Clicks and independent community pharmacies all dispense these medicines against a doctor-confirmed treatment plan, and licensed courier pharmacies deliver monthly in cold-chain packaging for people far from a branch. No lawful seller, online or physical, supplies a Schedule 4 medicine directly to the public.

That makes the red flags easy to spot. Websites or social media sellers offering the injections without any doctor involved, "compounded" semaglutide or tirzepatide at a fraction of pharmacy prices, or imports in unmarked packaging: none of these are SAHPRA-registered products, their contents are unverified, and South African regulators have warned the public against them. Suspicious sellers can be reported to SAHPRA's 24-hour hotline on 0800 204 307.

How to tell a legitimate online route from a dangerous one is covered in can you buy Ozempic online legally and safely.

What does GLP-1 treatment cost in South Africa?

Three components, paid to three different parties. Doctor care: consultation fees for the initial assessment and the follow-up reviews that ongoing treatment requires. The medicine: paid to the pharmacy at its regulated price, and the largest component by far. Blood tests: paid to a pathology lab, per test, usually once at baseline.

Medical aid rarely funds the medicine for weight management, because obesity is not a Prescribed Minimum Benefit condition, though consultations and blood tests often go through day-to-day benefits or savings.

Published pharmacy price ranges for each medicine, why prices differ and how to budget across the first six months are covered in what GLP-1 treatment costs in South Africa. Prices vary by pharmacy and dose; confirm any figure with your pharmacy.

What did the WHO decide about GLP-1 medicines?

In September 2025 the World Health Organization added four medicines in this class, semaglutide, liraglutide, dulaglutide and tirzepatide, to its Model List of Essential Medicines. The listing covers adults with type 2 diabetes who also have cardiovascular disease or chronic kidney disease and obesity.

The WHO followed in December 2025 with its first global guideline on using GLP-1 medicines to treat obesity, framing obesity as a chronic disease needing long-term care and stating that access should be prioritised by clinical need rather than ability to pay.

Why this matters here: the WHO list is the reference document national committees consult when deciding what public health systems should stock. A listing forces no country's hand, but it strengthens the case in front of South Africa's National Essential Medicines List Committee, and the WHO paired it with a call for generic competition to bring prices down, which is precisely the dynamic now starting in South Africa.

Is GLP-1 available in the public sector in South Africa?

No, not in 2026. No GLP-1 medicine is stocked in South Africa's public sector, so the clinics and hospitals that serve most of the population cannot supply them, whatever the clinical need. Access today is private: a doctor's assessment, then a pharmacy at the regulated price.

The numbers behind the debate are stark. Around 28% of South African adults live with obesity, including some 43% of women, and Spotlight reports that researchers estimate roughly 12 million people could meet treatment criteria if obesity plus a condition such as high blood pressure or diabetes qualified.

Officially, the National Essential Medicines List Committee is prioritising a review of the class for public sector inclusion, with no committed timeline. Affordability is the obstacle, which is why the WHO listing, the 2027 patent horizon and the first generic approvals all matter: they are the mechanisms most likely to move these medicines within reach of the public system. Until that changes, the routes and costs in this guide are private sector realities.

What are the side effects of GLP-1 medication?

Mostly digestive and mostly temporary. Nausea, diarrhoea, constipation and vomiting lead the list across the class, clustering around dose increases and settling as the body adjusts. Doses start low and step up gradually precisely to keep this manageable.

Rare but serious problems have clear signals: severe, persistent stomach pain radiating to the back, vomiting that will not stop, or sudden vision loss in one eye all mean seek medical care immediately.

Some people should not use this class at all: anyone pregnant, trying to conceive or breastfeeding, and anyone with a personal or family history of medullary thyroid cancer or MEN2 syndrome. The doctor's screening covers this before any treatment plan is confirmed. The full guide, including home management tactics, is GLP-1 side effects and how to manage them.

What happens if you miss a GLP-1 dose?

Do not double up, ever: the fix for a missed dose is never two injections close together. Beyond that rule, the window depends on the product. Mounjaro's professional information allows a missed weekly dose to be taken within four days, after which it is skipped and the normal schedule resumes. Other products in the class set their own windows, printed in each patient leaflet, so check yours rather than borrowing a neighbour's rule.

Longer gaps need a doctor. After several missed weeks, the body's tolerance to side effects fades, and treatment often restarts at a lower strength rather than jumping back to the previous dose. That is a clinical decision, not a judgement call at home.

Routine prevents most missed doses in the first place: a fixed injection day, a phone reminder, and collecting the next pen before the current one runs out. Technique and timing are covered in how to inject GLP-1 medicines.

What does starting GLP-1 treatment in South Africa involve?

Treatment always begins with a doctor's assessment. Three things make that assessment thorough: your weight and health history, a list of every medicine and supplement you take, and any recent blood results you have. That is what a doctor needs to judge whether treatment is appropriate and safe for you.

Set expectations for a process, not an event. The first months involve dose step-ups, a side-effect adjustment period and follow-up reviews, and the eating and activity habits you build alongside the medicine do a large share of the long-term work. A realistic first-year rhythm looks like this: assessment, a starting dose for about a month, reviews at each step up, and a settling dose held once results and side effects balance.

If you are still comparing options across the whole category, injectable and otherwise, the companion guide to this one is weight loss injections in South Africa.

Frequently asked questions